Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically

Tumori

Volumn 97, Issue 6, 2011, Pages 762-770

  Li, Shi Sheng ^a   Tang, Qing Lai ^a   Wang, Shu Hui ^a   Chen, Yue Hong ^a   Liu, Jia Jia ^a   Yang, Xin Ming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Akt; Bcl 2; Nasopharyngeal carcinoma; Resistance; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 9; DEATH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MORPHOLINES; NASOPHARYNGEAL NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 84863171959     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1018.11094     Document Type: Article

References (38)

1. Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, Liao X, Lin A, Liu M, Li L, Ma J: The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer, 115: 680-688, 2009.
2. Fiveash JB, Murshed H, Duan J, Hyatt M, Caranto J, Bonner JA, Popple RA: Effect of multileaf collimator leaf width on physical dose distributions in the treatment of CNS and head and neck neoplasms with intensity modulated radiation therapy. Med Phys, 29: 1116-1119, 2002. (Pubitemid 34670538)
3. Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI: Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope, 118: 663-670, 2008. (Pubitemid 351496779)
4. Caponigro F, Longo F, Ionna F, Perri F: Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs, 21: 471-477, 2010.
5. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 256: 42-49, 2000. (Pubitemid 30211165)
6. Walczak H, Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res, 256: 58-66, 2000. (Pubitemid 30211167)
7. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277: 815-818, 1997. (Pubitemid 27366732)
8. Green DR, Evan GI: A matter of life and death. Cancer Cell, 1: 19-30, 2002. (Pubitemid 41039172)
9. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998. (Pubitemid 28391864)
10. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K,Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med, 7: 383-385, 2001.
11. Teng MS, Brandwein Gensler MS, Teixeira MS, Martignetti JA, Duffey DC: A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, 131: 407-412, 2005. (Pubitemid 40638144)
12. Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, Van Oosten RL, Brincks EL, Norian LA: TRAIL gene therapy: from preclinical development to clinical application. Current Gene Therapy, 9: 9-19, 2009.
13. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol, 25: 1390-1395, 2007. (Pubitemid 46706887)
14. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene, 27: 2055-2063, 2008. (Pubitemid 351442738)
15. Chen MK, Lai JC, Chang CC, Chang JH, Chang YJ, Chen HC: Prognostic impact of Bcl-2 expression on advanced nasopharyngeal carcinoma. Head Neck, 10: 1052-1057, 2008.
16. Rokhlin OW, Guseva N, Tagiyev A, Knudson CN, Cohen MB: Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene, 20: 2836-2843, 2001. (Pubitemid 32549840)
17. Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, Izaki H, Fukumori T, Takahashi M, Nishitani M, Kanayama H: Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci, 10: 1093-1098, 2006. (Pubitemid 44322559)
18. Sarkar MC, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ, 11: 915-923, 2004. (Pubitemid 39139750)
19. Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S, Lammers R, Wesselborg S, Stork B: The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer, 125: 932-941, 2009.
20. Ozoren N, Fisher MJ, Kim K: Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol, 16: 917-925, 2000.
21. Zhang XM, Wang Q, Ling MT, Wong YC, Leung SC, Wang XH: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer, 120: 1891-1898, 2007. (Pubitemid 46418364)
22. Tschopp J, Irmler M, Thome M: Inhibition of fas death signals by FLIPs. Curr Opin Immunol, 10: 552-558, 1998. (Pubitemid 28479188)
23. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S, Peter ME, Yang X: c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J, 21: 3704-3714, 2002. (Pubitemid 34787044)
24. Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol, 3: 401-410, 2002. (Pubitemid 34685698)
25. Hengartner MO: The biochemistry of apoptosis. Nature, 407: 770-776, 2000.
26. Yin ZH, Ren CP, Li F, Yang XY, Li H, Zhao M, Yao KT: Suppression of Bcl-2 gene by RNA interference increases chemosensitivity to cisplatin in nasopharyngeal carcinoma cell line CNE1. Acta Biochim Biophys Sin (Shanghai), 36: 749-753, 2004. (Pubitemid 40395040)
27. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang DJ, Zeng YX: ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer, 123: 2418-2429, 2008.
28. Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 21: 2283-2294, 2002. (Pubitemid 34407288)
29. Cory S, Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell, 8: 5-6, 2005. (Pubitemid 40991809)
30. Brognard J, Clark AS, Ni Y, Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 61: 3986-3997, 2001. (Pubitemid 32720961)
31. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev, 13: 2905-2927, 1999.
32. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science, 282: 1318-1321, 1998. (Pubitemid 28524494)
33. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401: 82-85, 1999.
34. Kandasamy K, Srivastava RK: Role of the phosphatidylinositol 3'kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res, 62: 4929-4937, 2002. (Pubitemid 34984416)
35. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW, Lee BL: Upregulation of FLIP by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci, 94: 1066-1073, 2003. (Pubitemid 38035521)
36. Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs, 17: 261-268, 2006.
37. Degli Esposti M: The roles of Bid. Apoptosis, 7: 433-440, 2002.
38. Majewski N, Nogueira V, Robey RB, Hay N: Akt inhibits apoptosis downstream of Bid cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol, 24: 730-740, 2004. (Pubitemid 38057924)